Overview
Rivus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to advancing cardiometabolic health through the development of oral small-molecule therapeutics. The company specializes in controlled metabolic accelerators (CMAs), a novel class of medicines that leverage mitochondrial uncoupling to increase energy expenditure and promote fat-specific weight loss while preserving lean muscle mass. Rivus targets obesity and associated cardiometabolic diseases including metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF), and type 2 diabetes, with its lead candidate HU6 advancing through Phase 2 clinical trials. The company's approach addresses fundamental metabolic dysfunction by targeting mitochondrial biology, positioning it to address multiple age-related cardiometabolic conditions through a single therapeutic mechanism.